About biologic therapeutics
Biologic therapeutics include virus, therapeutic serums, toxins, allergenic products, antitoxin, blood components or derivatives, vaccines, blood, and proteins (except any chemically synthesized polypeptide). They also include analogous products, arsphenamine, or derivatives of arsphenamine (or any other trivalent organic arsenic compound) for the prevention, treatment, or cure of a disease. The differences between the biologics and small molecules include the molecular weight, structure, procedure of synthesis, and immunogenicity. Biologics have a higher molecular weight and a complex molecular structure. They are usually derived from living entities, which is another important feature that differentiates it from small molecules. Biologics are also vulnerable to extreme temperatures (thermolabile) and light.
Technavio's analysts forecast the global biologic therapeutics market to grow at a CAGR of 8.26% over the period 2014-2019.
Covered in this report
This report covers the present scenario and the growth prospects of the global biologic therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales protein therapeutics (monoclonal antibodies, enzymes, and other protein therapeutics).
Other protein therapeutics covers proteins such as cytokines, fusion proteins, peptide antibiotics, peptide hormones, and blood factors.
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. The vendor landscape section includes a market share analysis of the major vendors along with the competitive performances of their product portfolios. In addition, the report discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends emerging in the market.
Technavio's report, Global Biologic Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global biologic therapeutics market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Technavio Announces the Publication of its Research Report – Global Biologic Therapeutics Market 2015-2019
Technavio recognizes the following companies as the key players in the Global Biologic Therapeutics Market:
Other Prominent Vendors in the market are: Amgen, F. Hoffmann-La Roche, Novo Nordisk, and Sanofi.
Commenting on the report, an analyst from Technavio’s team said: “R&D in the market is rising in terms of the increasing collaborations between companies and the increase in mergers and acquisitions. For instance, in January 2014, Sanofi and Alnylam signed an agreement for the development of treatment therapies for rare genetic diseases.”
According to the report, Biologic therapeutics are expensive and cannot be afforded by all, but the reimbursement of diagnostic kits and biologic drugs is expected to drive the market during the forecast period.
Further, the report states that competition is a major challenge for the market and varies depending on the disease. However, the market competition is negligible for biologics such as Fabrazyme, which is the only approved therapy in the US for the treatment of Fabry disease.
Amgen, F. Hoffmann-La Roche, Novo Nordisk, Sanofi.